Impact Factor
3.23
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.46
18,440 total citations
h5-index
110
h5 depth signal
Cited share
20.4%
2,671 of 13,106
Total citations
18,440
Citation footprint
Metric signal
1.94
External metric anchor
Self-citation
9.4%
1,726 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
23,802
United Kingdom
4,931
Canada
3,806
Sweden
2,645
China
2,436
Citing Fields of Research
Neurodegenerative Disorders
37,863
Neurosciences
6,391
Palliative Care
2,711
Genetics & Genomics
1,830
Health Education & Remote Healthcare
1,704
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
65,614
Articles tracked across the journal lifetime
Indexed publication set
13,106
2,671 cited publications
Last 12 months
7,119
593.3 publications/month
Open access share
100.0%
7,118 OA publications in the last year
Leading citing country
United States
23,802 citing publications
Leading citing field
Neurodegenerative Disorders
37,863 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v4n1, Jan. 2008-
v4n1, Jan. 2008-
Active Coverage
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Issuing & Sponsoring Bodies
Contributor
Alzheimer's Association
Broad Categories
Neurology
Psychiatry
Neurodegenerative Disorders
MeSH Descriptors
Alzheimer Disease
Dementia
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/alz.71918
Open DOI
H3K9me3 inhibition reverses Alzheimer's progression by restoring synaptic and immune proteostasis across the brain–retina axis
INTRODUCTION: Epigenetic dysregulation is increasingly linked to aging and neurodegeneration, yet its contribution to retinal and brain pathology in Alzheimer's disease (AD) remains unclear. METHODS: We quantified the repressive epigenet...
02
DOI 10.1002/alz.71922
Open DOI
Direction‐specific biomarker profiles and clinical significance of plasma p‐tau217/amyloid PET discordance in cognitively normal adults
INTRODUCTION: Plasma phosphorylated tau (p‐tau)217 is increasingly used to triage amyloid testing, but the biological and clinical meaning of discordant plasma p‐tau217 and amyloid positron emission tomography (PET) results in cognitivel...
03
INTRODUCTION: Diabetes is a major risk factor for Alzheimer's disease (AD), and both diseases involve mitochondrial dysfunction. Changes in mitochondrial DNA (mtDNA) can influence energy metabolism, cellular signaling, and epigenetic pro...
04
DOI 10.1002/alz.71814
Open DOI
Analysis of dementia strategic plans in US states
State dementia strategic plans provide policy and practice recommendations to reduce the risk, progression, and impact of dementia. Yet there is little systematic understanding of the contents of state plans nor how they aim to influence...
05
DOI 10.1002/alz.71889
Open DOI
Integration of neuroimaging signatures of aging and Alzheimer's with fluid biomarkers
INTRODUCTION: Machine learning algorithms applied to neuroimaging may aid diagnosis and disease monitoring. This study aimed to derive neuroimaging signatures of brain aging (Spatial Pattern of Atrophy for Recognition–Brain Age [SPARE‐BA...
06
DOI 10.1002/alz.71847
Open DOI
The right temperature at the right time: A framework for understanding thermoregulatory pathophysiology in Alzheimer's disease
The neuromodulatory subcortical system (NSS) includes thermoregulatory neurons that maintain core body temperature (Tb) and brain temperature within a narrow, diurnally varying range. Cellular pathways in NSS neurons implicated in Alzhei...
07
DOI 10.1002/alz.71770
Open DOI
Attention‐deficit/hyperactivity disorder polygenic risk score and incidence of cognitive impairment in older adults: A prospective multicohort study
INTRODUCTION: Preliminary evidence suggests a link between attention‐deficit/hyperactivity disorder (ADHD) and later‐life cognitive impairment. Whether genetic risk for ADHD, estimated using an ADHD polygenic risk score (ADHD‐PRS), is as...
08
DOI 10.1002/alz.71837
Open DOI
Air pollution is associated with sex‐specific longitudinal changes in astrocytic and neuroinflammatory processes linked to cognitive decline in Alzheimer's disease at‐risk individuals
INTRODUCTION: Air pollution is associated with dementia risk, but its role during preclinical Alzheimer's disease (AD) remains unclear. METHODS: We examined long‐term residential exposure to traffic‐related air pollution in 226 cognitive...
09
DOI 10.1002/alz.71899
Open DOI
Brain microstructure mediates the relationship between Alzheimer's proteinopathies and memory
INTRODUCTION: We examined how amyloid beta (Aβ) and tau accumulation affected gray matter (GM) microstructural integrity and how such alterations impacted memory. METHODS: We tested voxel‐wise mediation models to examine the relationship...
10
DOI 10.1002/alz.71690
Open DOI
Sphingolipid and ceramide associations with tau pathology vary across diverse ethnoracial groups in postmortem brain tissue
INTRODUCTION: Metabolic dysregulation is a hallmark of Alzheimer's disease (AD), with numerous studies characterizing metabolic pathways associated with AD onset and progression. A limitation of these studies has been a focus on non‐Hisp...
Bibliographical & Catalog Notes
Latest issue consulted: Vol. 2, issue 2 (Apr. 2006).
Also issued online.
Companion to: Alzheimer's & dementia (New York, N. Y.).
Complemented by (work): Alzheimer's & dementia (New York, N. Y.) 2352-8737 (DLC) 2015247808 (OCoLC)914282383 (DNLM)101650118.